News

The trial is designed to evaluate the safety, tolerability and immunogenicity of ChimeriVax-West Nile in older adults and is being conducted in the US. The randomized, double-blind, placebo-controlled

Under the offer, valued at $11.1 million, NeuroMedix common shareholders can receive one common share of Transition for every 5.1429 NeuroMedix common shares tendered. The company's directors, officers

The drug is an anthrax immune globulin (AIG) therapeutic treatment for patients who present with symptoms of anthrax disease resulting from the release of anthrax toxins into the

The biopharmaceutical firm said the offering would raise up to $86.25 million, although the company has not revealed how many shares it is planning to sell in the

The study, published in the journal Molecular Psychiatry, compared genetic variants in individuals with schizophrenia to individuals who do not have the disease. Sequencing revealed specific genetic variants

In addition to the RSV collaboration, the biopharmaceutical firm is working with the institute on the clinical development of HIV and influenza vaccines. “Data emerging from the clinical

Californian biopharmaceutical company Pain Therapeutics’ initial phase I study is designed to evaluate the pharmacokinetics of a proprietary radio-labeled monoclonal antibody in patients diagnosed with metastatic melanoma. The

Riquent is being developed to specifically treat lupus renal disease by preventing or delaying renal flares. A lupus renal flare is a potentially life-threatening increase in inflammation targeting

Over 800 patients with mild Alzheimer's disease enrolled in the study will take 800 mg twice daily of either Flurizan or placebo and attend periodic physician visits for